Long non-coding RNA LINC00680 functions as a ceRNA to promote esophageal squamous cell carcinoma progression through the miR-423-5p/PAK6 axis

Xue, Songtao; Zheng, Bin; Cao, Shi-Qiang; Ding, Jian; Hu, Guo-Sheng; Liu, Wen; Chen, Chun

doi:10.1186/s12943-022-01539-3

Cited by 72 publications

(51 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MiRNA expression is also regulated by DNA methylation ( 49 ). In recent years, many studies have found that long noncoding RNAs (lncRNAs) have the role of sponge, they can competitively adsorb miRNA, thereby inhibiting the regulation of miRNA on target genes ( 50 , 51 ). In future research, we will explore the causes and mechanisms of miR-375 expression changes in tumors from an epigenetic perspective and explore the feasibility of miRNA-375 as an anti-tumor drug.…”

Section: Discussionmentioning

confidence: 99%

miR-375 suppresses the growth and metastasis of esophageal squamous cell carcinoma by targeting PRDX1

Liu¹,

Zhang²,

Zhou³

et al. 2022

J Gastrointest Oncol

View full text Add to dashboard Cite

Background: Esophageal cancer (EC) is one of the most lethal cancers. Esophageal squamous cell carcinoma (ESCC) is the most common histological subtype in Asian people. Diverse microRNAs, such as miR-375, have been confirmed to be involved in the process of tumorigenesis and metastasis. However, the underlying mechanism through which miR-375 acts in ESCC patients remains unknown. Methods: We used The Cancer Genome Atlas (TCGA) database to analyze the association between miR-375 and the survival rate in patients with esophageal squamous cell carcinoma. Real Time quantitative PCR (RT-qPCR) analysis was performed to evaluate the level of miR-375 in EC tissues and cells. A luciferase reporter assay was used to confirm the target gene of miR-375. A colony formation assay as well as flow cytometric and transwell invasion experiments were employed to examine the effects of miR-375 and peroxiredoxin 1 (PRDX1) on ESCC cells. A tumor xenograft mouse model was then used to investigate the role of miR-375 on tumor growth in vivo. Moreover, we performed rescue experiments to evaluate the effect of PRDX1 on ESCC progression. Results: miR-375 expression was significantly downregulated in both ESCC clinical tissues and serum, and the reduction of miR-375 was remarkably linked to a poor prognosis in ESCC. Further investigation illustrated that aberrant expression of miR-375 dampened the growth and infiltration of ESCC cells both in vitro and in vivo. Bioinformatics and luciferase reporter analysis verified that the transcript of PRDX1 is a direct target of miR-375 and its expression in ESCC cells was found to be inversely modulated by miR-375. Moreover, the tumor formation experiment in nude mice confirmed that miR-375 can effectively dampen tumor growth in xenograft tumor mice models. Notably, over-expression of PRDX1 effectively counteracted the tumor-suppressing capabilities of miR-375. Conclusions: We demonstrated the antitumor effect of miR-375 on ESCC by targeting PRDX1 both in vitro and in vivo.

show abstract

Section: Discussionmentioning

confidence: 99%

miR-375 suppresses the growth and metastasis of esophageal squamous cell carcinoma by targeting PRDX1

Liu¹,

Zhang²,

Zhou³

et al. 2022

J Gastrointest Oncol

View full text Add to dashboard Cite

show abstract

“…Apolipoprotein C2 (APOC2) is a lipoprotein lipase activator involved in fatty acid metabolism [ 45 ]. Most differentially expressed lncRNAs, such as AL121906.2 [ 46 ], AC092910.3 [ 47 ], AC005332.4 [ 48 ], and CASC9 [ 49 ], were upregulated in EAC subtype 1 and had been previously reported as prognostic biomarkers in multiple tumors. These findings highlighted the intrinsic molecular differences between the two EAC subtypes.…”

Section: Discussionmentioning

confidence: 99%

Identification of Immune Subtypes of Esophageal Adenocarcinoma to Predict Prognosis and Immunotherapy Response

et al. 2022

View full text Add to dashboard Cite

A low response rate limits the application of immune checkpoint inhibitors (ICIs) in the treatment of esophageal adenocarcinoma (EAC), which requires the precise characterization of heterogeneous tumor microenvironments. This study aimed to identify the molecular features and tumor microenvironment compositions of EAC to facilitate patient stratification and provide novel strategies to improve clinical outcomes. Here, we performed consensus molecular subtyping with nonnegative matrix factorization (NMF) using EAC data from the Cancer Genome Atlas (TCGA) and identified two distinct subtypes with significant prognostic differences and differences in tumor microenvironments. The findings were further validated in independent EAC cohorts and potential response to ICI therapy was estimated using Tumor Immune Dysfunction and Exclusion (TIDE) and SubMap methods. Our findings suggest that EAC patients of subtype 2 with low levels of cancer-associated fibroblasts, tumor associated macrophages (TAMs), and MDSCs in the tumor microenvironment may benefit from PD-1 blockade therapy, while patients of subtype 1 are more responsive to chemotherapy or combination therapy. These findings might improve our understanding of immunotherapy efficacy and be useful in the development of new strategies to better guide immunotherapy and targeted therapy in the treatment of EAC.

show abstract

“…As one of the common types of genetic medicines, microRNAs (miRNAs) are a group of non-coding small RNAs with a length of about 22 bp that silence target genes at the post-transcriptional level [7]. Current research confirms that miRNAs are involved in many physiological processes and pathological pathways, including embryonic development, tumorigenesis, and cardiac disease [8][9][10]. Studies have confirmed that in the brain tissue or serum of AD patients, many miRNAs have been identified as down-regulated and thought to be involved in the formation of senile plaques and neurofibrillary tangles [11].…”

Section: Introductionmentioning

confidence: 99%

MicroRNA-22-3p ameliorates Alzheimer’s disease by targeting SOX9 through the NF-κB signaling pathway in the hippocampus

Xia

Chen

Liu

et al. 2022

J Neuroinflammation

View full text Add to dashboard Cite

Background Studies have suggested that many down-regulated miRNAs identified in the brain tissue or serum of Alzheimer’s disease (AD) patients were involved in the formation of senile plaques and neurofibrillary tangles. Specifically, our previous study revealed that microRNA-22-3p (miR-22-3p) was significantly down-regulated in AD patients. However, the molecular mechanism underlying the down-regulation of miR-22-3p has not been comprehensively investigated. Methods The ameliorating effect of miR-22-3p on apoptosis of the Aβ-treated HT22 cells was detected by TUNEL staining, flow cytometry, and western blotting. The cognition of mice with stereotaxic injection of agomir or antagomir of miR-22-3p was assessed by Morris water maze test. Pathological changes in the mouse hippocampus were analyzed using hematoxylin and eosin (HE) staining, Nissl staining, and immunohistochemistry. Proteomics analysis was performed to identify the targets of miR-22-3p, which were further validated using dual-luciferase reporter analysis and western blotting analysis. Results The miR-22-3p played an important role in ameliorating apoptosis in the Aβ-treated HT22 cells. Increased levels of miR-22-3p in the mouse hippocampus improved the cognition in mice. Although the miR-22-3p did not cause the decrease of neuronal loss in the hippocampus, it reduced the Aβ deposition. Proteomics analysis revealed Sox9 protein as the target of miR-22-3p, which was verified by the luciferase reporter experiments. Conclusion Our study showed that miR-22-3p could improve apoptosis and reduce Aβ deposition by acting on Sox9 through the NF-κB signaling pathway to improve the cognition in AD mice. We concluded that miR-22-3p ameliorated AD by targeting Sox9 through the NF-κB signaling pathway in the hippocampus.

show abstract

Long non-coding RNA LINC00680 functions as a ceRNA to promote esophageal squamous cell carcinoma progression through the miR-423-5p/PAK6 axis

Cited by 72 publications

References 94 publications

miR-375 suppresses the growth and metastasis of esophageal squamous cell carcinoma by targeting PRDX1

miR-375 suppresses the growth and metastasis of esophageal squamous cell carcinoma by targeting PRDX1

Identification of Immune Subtypes of Esophageal Adenocarcinoma to Predict Prognosis and Immunotherapy Response

MicroRNA-22-3p ameliorates Alzheimer’s disease by targeting SOX9 through the NF-κB signaling pathway in the hippocampus

Contact Info

Product

Resources

About